Business Description
Heron Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US4277461020
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.45 | |||||
Equity-to-Asset | -0.15 | |||||
Debt-to-Equity | -5.29 | |||||
Debt-to-EBITDA | -1.73 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -11.55 | |||||
Beneish M-Score | -3.66 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2 | |||||
3-Year EBITDA Growth Rate | 32.6 | |||||
3-Year EPS without NRI Growth Rate | 31.6 | |||||
3-Year FCF Growth Rate | 40.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 18.77 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.37 | |||||
9-Day RSI | 49.98 | |||||
14-Day RSI | 48.63 | |||||
6-1 Month Momentum % | 238.26 | |||||
12-1 Month Momentum % | 17.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 1.84 | |||||
Cash Ratio | 1.01 | |||||
Days Inventory | 263.91 | |||||
Days Sales Outstanding | 174.75 | |||||
Days Payable | 17.12 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.1 | |||||
Shareholder Yield % | -2.52 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.75 | |||||
Operating Margin % | -87.07 | |||||
Net Margin % | -87.02 | |||||
FCF Margin % | -47.63 | |||||
ROA % | -49.15 | |||||
ROIC % | -133.06 | |||||
ROC (Joel Greenblatt) % | -156.16 | |||||
ROCE % | -74.26 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.73 | |||||
EV-to-EBIT | -4.62 | |||||
EV-to-EBITDA | -4.74 | |||||
EV-to-Revenue | 3.88 | |||||
EV-to-FCF | -8.16 | |||||
Earnings Yield (Greenblatt) % | -21.65 | |||||
FCF Yield % | -15.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Heron Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 117.822 | ||
EPS (TTM) (€) | -0.78 | ||
Beta | 2.6 | ||
Volatility % | 143.39 | ||
14-Day RSI | 48.63 | ||
14-Day ATR (€) | 0.116946 | ||
20-Day SMA (€) | 2.4599 | ||
12-1 Month Momentum % | 17.88 | ||
52-Week Range (€) | 0.498 - 2.82 | ||
Shares Outstanding (Mil) | 150.64 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Heron Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Heron Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Heron Therapeutics Inc Frequently Asked Questions
What is Heron Therapeutics Inc(STU:AXD2)'s stock price today?
When is next earnings date of Heron Therapeutics Inc(STU:AXD2)?
Does Heron Therapeutics Inc(STU:AXD2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |